EMEA-002661-PIP01-19 - paediatric investigation plan

Autologous haptenised and irradiated cells derived from glioma

Key facts

• Active Substance:
  Autologous haptenised and irradiated cells derived from glioma
• Therapeutic area:
  Oncology
• Decision number:
  P/0226/2020
• PIP number:
  EMEA-002661-PIP01-19
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of glioma
• Route(s) of administration:
  Intradermal use
• Contact for public enquiries:

  ERC Belgium

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  17/06/2020

Decision

P/0226/2020: EMA decision of 17 June 2020 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for autologous haptenised and irradiated cells derived from glioma (EMEA-002661-PIP01-19)

AdoptedReference Number: EMA/259751/2020